ReShape Lifesciences completed a merger with Vyome Therapeutics and is now known as Vyome Holdings, fundamentally transforming the business from weight-loss solutions to what appears to be a therapeutics company.
This represents a complete business transformation through merger, evidenced by the dramatic operational changes and new corporate identity. The significant deterioration in financial performance and shift to negative stockholders' equity suggests the combined entity is struggling post-merger and may face substantial execution challenges in the new business model.
The company shows severe financial distress with stockholders' equity plummeting to negative $253K from positive $6.7M, while gross profit collapsed 96% to just $219K despite maintaining $5M in cash. Net losses deepened by 44% to $10.3M as SG&A expenses more than doubled, and accounts receivable essentially disappeared, indicating a complete business model shift. The overall picture signals a company in financial turmoil following a transformative merger, with cash providing temporary stability but underlying operations generating massive losses.
Cash position surged 619% — strong cash generation or capital raise providing significant financial cushion.
SG&A up 163.3% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
R&D spending cut 67.4% — could signal cost discipline or concerning reduction in innovation investment.
Liabilities reduced 45.8% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
Net income declined 43.9% — review whether driven by operations, interest costs, or non-recurring items.
Asset base grew 35.6% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →